Where positive effects have been observed, the magnitude of weight loss is typically smallgenerally in the range of 0.5-2 kgwhich may not be clinically meaningful for most individuals seeking weight management
reported an observational comparative study that compared nerve excitability in patients with type 2 DM who received exenatide (n=32), a dipeptidyl peptidase-4 (DPP-4) inhibitor (n=31), or a sodium-glucose cotransporter-2 (SGLT-2) inhibitor (n=27) (59)
When signaling efficiency declines, the effects often appear gradually
Here the gastroesophageal junction is in the abdomen but a portion of the stomach sneaks around the esophagus and up in the chest
Mitchell JR, Jallow DJ, Potter WZ, Gillette JR and Brodie BB
DS-1062), a TROP2 ADC, in patients with advanced NSCLC: updated results of TROPION-PanTumor01 phase 1 study